CADILA HEALTHCARE LTD. - 532321 - Transcript
Transcript of investor call held on February 3, 202210-02-2022
10-02-2022
Accumulate Cadila Healthcare; target of Rs 445: KR Choksey
KR Choksey recommended accumulate rating on Cadila Healthcare with a target price of Rs 445 in its research report dated February 07, 2022.07-02-2022
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of share certificate05-02-2022
Buy Cadila Healthcare; target of Rs 560: Sharekhan
Sharekhan is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 560 in its research report dated February 03, 2022.04-02-2022
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication with regard to publication of extracts of unaudited financial results for the quarter / nine months ended on December 31, 202104-02-2022
Cadila: Biosimilars, oncology portfolio hold promise for medium term
The Moraiya plant's pending USFDA approval is crucial for Cadila's US ambition04-02-2022
Earnings Call for Q3FY22 of Cadila Healthcare
Conference Call with Cadila Healthcare Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.03-02-2022
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on the unaudited financial results for the quarter ended on December 31, 202103-02-2022
Q3FY22 Quarterly Result Announced for Cadila Healthcare Ltd.
Pharmaceuticals company Cadila Healthcare declares Q3FY22 result: Zydus posts consolidated revenues of Rs. 3655 crores in Q3 Earnings before Interest, Depreciation and Tax (EBIDTA) stood at Rs. 753 crores. Net Profit for the quarter stood at Rs. 500 crores. India formulations business posted revenues of Rs. 1079 crores during the quarter. The branded formulations business posted a robust double-digit growth of 17% on a YoY basis. This is after adjusting for sales of COVID related products, generics portfolio and divested products. The company’s patented product ‘Lipaglyn’ entered the top 100 brands of the Indian pharmaceutical market and was ranked at 92. This is a jump of 183 ranks i.e. from 275 to 92 during the current quarter. On the super specialty front, the group retained the leadership position in the Nephrology market and in the oncology segment, the group is the fastest growing company in India. The group gained market share in the core therapies of anti-diabetic, cardiovascular, gynaecology and anti-infective therapeutic areas during the quarter on a YoY basis. US formulations business registered revenues of Rs.1504 crores during the quarter. The company filed 12 additional ANDAs with the USFDA during the quarter and received 9 new product approvals (including 5 tentative approvals) from the USFDA. The company launched 3 new products in the US market including Nelarabine injection which was granted 180 days exclusivity and was a day 1 launch. It is a chemotherapy drug used to treat certain types of leukemia and lymphoma. During the quarter, the company announced positive clinical data for CUTX-101, Copper Histidinate, presented at 2021 American Academy of Pediatrics National Conference & Exhibition. Cyprium Therapeutics Inc., a partner company of Fortress Biotech Inc., with support from its licensing partner Sentynl Therapeutics, a wholly owned subsidiary of CHL is developing CUTX-101 for the treatment of Menkes disease. An initial module of a New Drug Application (NDA) of CUTX 101 was also filed with the USFDA during the quarter. Result PDF03-02-2022
CADILA HEALTHCARE LTD. - 532321 - The Unaudited Financial Results (Standalone And Consolidated) For The Quarter / Nine Months Ended On December 31, 2021
The unaudited financial results (standalone and consolidated) for the quarter / nine months ended on December 31, 202103-02-2022